The immune system does not retire at 110

Aging biology is overdue for a different working model. The immune system has long been treated as a system in retreat across the life course: fewer naive cells, a narrower repertoire, slower responses with each decade. New single-cell data from a Cell Reports study led by Kosuke Hashimoto at the University of Osaka challenges that read.

In blood samples from 28 adults, the share of CD4 cytotoxic T lymphocytes rose with each age bracket, climbing from a median of 4% in adults 70-99, to 9.6% in people 100-109, to 17.6% in those 110 and older. Many of those cells had expanded into large clonal populations, which is the signature of an immune system still responding to live threats. The mechanism is familiar: clonal expansion is how T cells multiply when they recognize a target, then persist as memory. What is new is seeing it scale into the oldest cohort instead of fading.

Hashimoto frames the finding bluntly: "Immune aging is not simply a process of decline. The immune system may continue to adapt to age-related challenges." A small sample, a correlation, and one under-100 participant with the highest CD4 CTL share of anyone studied, which means the pattern is not strictly age-gated. The biology of growing old reads better as selective adaptation alongside decay, with the immune system still building capacity where the threats are persistent.